MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2026.1896560

Медицинская библиотека · Frontiers in immunology · 2026

Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review.

Allinovi Marco, Lomi Jacopo, Accinno Matteo, Teisseyre Maxime, Diomaiuti Michael, Madeo Raffaele, Allegretta Federica, Matucci Andrea, Vultaggio Alessandra

СтатьяОбзорПеревод в очереди

Аннотация

Rituximab is a chimeric anti-CD20 monoclonal antibody widely used in immune-mediated and hematologic diseases, but its efficacy may be limited by the development of anti-rituximab antibodies (ADAs). This narrative review summarizes current evidence on the incidence, detection, and clinical implications of ADAs in nephropathies and other immune-mediated disorders. ADA prevalence varies markedly across diseases and is influenced by assay methodology, timing of testing, and patient immune background. Although not all ADAs are clinically relevant, their presence has been associated with lower rituximab levels, earlier B-cell repopulation, reduced clinical/immunological remission, more frequent relapses, and hypersensitivity reactions. Overall, ADAs represent an underrecognized factor that may affect rituximab efficacy and safety, supporting the need for improved monitoring and more personalized therapeutic strategies.

Для цитирования: Allinovi Marco, Lomi Jacopo, Accinno Matteo, Teisseyre Maxime, Diomaiuti Michael, Madeo Raffaele, Allegretta Federica, Matucci Andrea, Vultaggio Alessandra. Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1896560.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.